WhiteLab Genomics
WhiteLab Genomics, based in Paris and Boston, is a healthcare company specializing in the discovery and delivery of genomic therapies using AI to accelerate development in the field.
Company Overview
WhiteLab Genomics operates in the healthcare sector, specifically focusing on drug discovery and delivery. The company aims to revolutionize genomic therapies through advanced technologies. Locations include Paris, Île-de-France, France, and Boston, MA, USA. The team consists of 25 members. WhiteLab Genomics is an early-stage company part of Y Combinator's W22 batch and maintains a broad regional presence across France, the United States, Europe, and beyond with options for remote and partly remote work.
Genomic Therapy Solutions
WhiteLab Genomics specializes in accelerating the development of genomic and cell therapies. The company leverages a proprietary AI platform to enhance DNA and RNA-based therapies. Their focus areas include Cell Therapies, RNA Therapies, and DNA Therapies. The technology helps optimize payload and vector design and solve various scientific and technological challenges such as genotoxicity assessments and identification of optimal experimental protocols.
AI and Machine Learning Platform
The cornerstone of WhiteLab Genomics' innovative approach is its AI platform. This platform employs graph knowledge technology and machine learning to facilitate the discovery and design of new genomic therapies. It offers in-silico simulations that use extensive datasets to optimize payloads and vectors, aiming to accelerate the development process of genomic medicines.
Global Reach and Collaboration
WhiteLab Genomics has a strong global presence, actively operating in France, the United States, Europe, and other regions. The company is also involved in key partnerships with notable organizations including EIT Health, Institut du Cerveau - ICM, Medicen Paris Region, Genopole, STATION F, Wilco, Bpifrance, NIST, AI for Health, and Y Combinator. These collaborations support its mission to develop innovative genomic therapies.
Y Combinator and Industry Partnerships
WhiteLab Genomics was selected for Y Combinator's prestigious W22 batch, which provides a platform for early-stage companies to accelerate their growth. In addition to Y Combinator, the company collaborates with a range of partners such as EIT Health, Institut du Cerveau - ICM, and Bpifrance. These partnerships are pivotal in bolstering its development efforts and expanding the impact of its genomic therapy solutions.